Substituted pyrazoles, compositions containing these, method of production and use

1. A compound of formula (I):

wherein:

1) A and Ar are independently selected from the group consisting of: aryl, and substituted aryl,

2) L is O—CO—NH;

3) R 1 is selected from the group consisting of: H, R 6 , COR 6 , SO 2 R 6 , in which R 6 is chosen from H, OR 7 , NR 8 R 9 , alkyl, cycloalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl and substituted heteroaryl, in which R 7 is chosen from H, phenyl and alkyl, and in which R 8 and R 9 are independently selected from the group consisting of H, alkyl, cycloalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl and substituted heteroaryl, or alternatively R 8 and R 9 are linked together to form a saturated 5- to 8-membered ring containing from 0 to 3 heteroatoms chosen from O, S and N;

4) X is selected from the group consisting of: O and NH;

5) R 3 is selected from the group consisting of H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl;

6) R 4a is selected from the group consisting of: H and (C1-C4)alkyl;

7) R 4b is selected from the group consisting of: H and (C1-C4)alkyl;

8) R 5 is selected from the group consisting of H, halogen, R 10 , CN, O(R 10 ), OC(O)(R 10 ), OC(O)N(R 10 )(R 11 ), OS(O 2 )(R 10 ), N(R 10 )(R 11 ), N═C(R 10 )(R 11 ), N(R 10 )C(O)(R 11 ), N(R 10 )C(O)O(R 11 ), N(R 12 )C(O)N(R 10 )(R 11 ), N(R 12 )C(S)N(R 10 )(R 11 ), N(R 10 )S(O 2 )(R 11 ), C(O)(R 10 ), C(O)O(R 10 ), C(O)N(R 10 )(R 11 ), C(═N(R 11 ))(R 10 ), C(═N(OR 11 ))(R 10 ), S(R 10 ), S(O)(R 10 ), S(O 2 )(R 10 ), S(O 2 )O(R 10 ), S(O 2 )N(R 10 )(R 11 ); in which each R 10 , R 11 , R 12 is independently selected from the group consisting of H, alkyl, alkylene, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl, substituted alkyl, substituted alkylene, substituted alkynyl, substituted aryl, substituted heteroaryl, substituted cycloalkyl and substituted heterocyclyl.

2. The compound according to claim 1 , wherein R 4a and R 4b are H.

3. The compound according to claim 1 , wherein R 4a is H and R 4b is (C1-C4)alkyl.

4. The compound according to claim 1 , wherein R 4a is (C1-C4)alkyl and R 4b is H.

5. The compound according to claim 1 , wherein R 1 is H.

6. The compound according to claim 1 , wherein R 3 is H and X is NH.

7. The compound according to claim 1 , wherein R 3 is methyl and X is O.

8. The compound according to claim 1 , wherein R 5 is H.

9. The compound according to claim 1 , wherein Ar-L-A is:

in which each X 1 , X 2 , X 3 and X 4 is independently chosen from C—R′ 5 , in which R′ 5 has the same definition as R 5 .

10. The compound according to claim 9 , characterized in that R′ 5 is selected from the group consisting of H, F, Cl, methyl, NH 2 , OCF 3 and CONH 2 .

11. The compound according to claim 9 , characterized in that A is chosen from phenyl, optionally substituted.

12. The compound according to claim 1 , wherein A is substituted with one or more substituents selected from the group consisting of: H, F, Cl, Br, I, OH, SH, SO 3 M, COOM, COO-alkyl, CON(R 14 )(R 15 ), CN, NO 2 , N(R 14 )CO(R 15 ), N(R 14 )(R 15 ), alkyl, haloalkyl, alkyl-OH, alkyl-N(R 14 )(R 15 ), alkyl(R 16 ), alkyl-COOM, alkyl-SO 3 M, cycloalkyl, alkylene, alkynyl, aryl, heteroaryl, O-alkyl, O-aryl, O-heteroaryl, S-alkyl, S-aryl and S-heteroaryl, each being optionally substituted with a substituent chosen from alkyl, halogen, O-alkyl and N(R 14 )(R 15 ); in which R 14 and R 15 are independently chosen from H, alkyl, alkyl-OH, haloalkyl, alkyl-NH 2 , alkyl-COOM and alkyl-SO 3 M; in which, when R 14 and R 15 are simultaneously other than H, may be bonded to form a 5- to 7-membered ring comprising from 0 to 3 heteroatoms chosen from 0, N and S; in which M is H or a cation of an alkali metal chosen from Li, Na and K; and in which R 16 is H or an optionally substituted non-aromatic heterocycle, containing from 2 to 7 carbon atoms, and 1 to 3 heteroatoms chosen from N, O and S; when A is disubstituted, the two substituents may be linked together to form a 5- to 7-membered ring containing from 0 to 3 heteroatoms chosen from N, O and S.

13. The compound according to claim 1 , wherein A is substituted with one or more substituents selected from the group consisting of SiMe 3 , S—CHF 3 , SF 5 , H, F, Cl, Br, I, OH, SH, SO 3 M, COOM, COO-alkyl, CON(R 14 )(R 15 ), CN, NO 2 , N(R 14 )CO(R 15 ), N(R 14 )(R 15 ), alkyl, haloalkyl, alkyl-OH, alkyl-N(R 14 )(R 15 ), alkyl(R 16 ), alkyl-COOM, alkyl-SO 3 M, cycloalkyl, alkylene, alkynyl, aryl, heteroaryl, O-alkyl, O-aryl, O-heteroaryl, S-alkyl, S-aryl and S-heteroaryl, each being optionally substituted with a substituent chosen from alkyl, halogen, O-alkyl and N(R 14 )(R 15 ); wherein R 14 and R 15 are independently chosen from H, alkyl, alkyl-OH, haloalkyl, alkyl-NH 2 , alkyl-COOM and alkyl-SO 3 M; wherein, when R 14 and R 15 are simultaneously other than H, they may be bonded to form a 5- to 7-membered ring comprising from 0 to 3 heteroatoms chosen from 0, N and S; wherein M is H or a cation of an alkali metal chosen from Li, Na and K; and wherein R 16 is H or an optionally substituted non-aromatic heterocycle, containing from 2 to 7 carbon atoms, and 1 to 3 heteroatoms chosen from N, O and S; when A is disubstituted, the two substituents may be linked together to form a 5- to 7-membered ring containing from 0 to 3 heteroatoms chosen from N, O and S; or a salt thereof.

14. The compound according to claim 1 , which is:

4-{[3-phenyl]carbamoyl}oxy)benzyl]amino-1H-pyrazole-3-carboxamide trifluoroacetate.

15. The compound according to claim 1 , wherein it is:

1) in non-chiral form, or

2) in racemic form, or

3) enriched in one stereoisomer, or

4) enriched in one enantiomer;

and in that it is optionally salified.

16. A pharmaceutical composition comprising a product according to claim 1 , or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable excipient.

17. A pharmaceutical composition comprising a product according to claim 14 , or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable excipient.

18. A method for inhibiting one or more reactions catalysed by a kinase, comprising contacting said kinase with a compound according to claim 1 or a pharmaceutically acceptable salt thereof.

19. The method of claim 18 , wherein the kinase is chosen from KDR and Tie2.

20. A method for treating a patient having a pathological condition in which receptors of KDR are involved, comprising administering to said patient a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof.

21. The method according to claim 20 , wherein the pathological condition is cancer.

22. A process for preparing the compounds of formula (Ib):

in which R 1 , R 3 , R 4b , R 5 , X, Ar, L and A are as defined in claim 1 , and R 4a is H, characterized in that a compound of formula (II):

in which R′ 3 is R 3 or a precursor of R 3 , and X, R 1 , R 3 and R 5 are as defined in claim 1 , reacts with a compound of formula (III):

in which R 4b , Ar, L and A are as defined in claim 1 , to give the compound of formula (Ib).

23. A process for preparing the compounds of formula (I):

in which R 1 , R 3 , R 4a , R 4b , R 5 , X, Ar and A are as defined in claim 1 , and L is NHCONH, characterized in that a compound of formula (VIII):

in which R′ 3 is R 3 or a precursor of R 3 , and X, Ar, R 1 , R 3 , R 4a , R 4b and R 5 are as defined in claim 1 , reacts with a compound of formula (VII):

in which A is as defined in claim 1 , to give the compound of formula (I′)

in which the precursor R′ 3 is transformed into R 3 in order to obtain the compound of formula (I).